Gotu Kola: Evidence Review of Cognitive, Collagen, and Adaptogenic Effects

This article is for educational and research purposes only and does not constitute medical advice. Consult a qualified healthcare practitioner before using gotu kola, particularly if you are pregnant, have liver disease, or are taking prescription medications.

Gotu kola (Centella asiatica) occupies a rare position in traditional medicine: it is one of the few herbs that appears in both the Ayurvedic and traditional Chinese medicine pharmacopoeias as a primary agent for brain health, wound healing, and longevity. The Sinhalese have a saying — "two leaves a day keeps old age away" — a reference to the practice of eating fresh gotu kola leaves as a daily food and medicine. In Indian Ayurveda, it sits alongside ashwagandha and brahmi as a core medhya rasayana — a class of herbs specifically indicated for enhancing intellect and memory.

One clarification that matters before going further: gotu kola is not related to kola nut (Cola nitida), the caffeine-containing seed used in cola beverages. The naming overlap causes persistent consumer confusion. Gotu kola is caffeine-free and has mild calming rather than stimulant properties. The two plants belong to entirely different botanical families and share nothing pharmacologically relevant.

Modern phytochemical research has now identified the specific compounds responsible for gotu kola's traditional reputation, and a growing body of clinical evidence — while still maturing — provides meaningful support for its use in cognitive health, wound repair, collagen synthesis, and venous circulation. This review examines that evidence systematically.

Plant Chemistry: The Triterpenoid Core

Gotu kola's pharmacology is dominated by a family of pentacyclic triterpenoid saponins that are unique to Centella asiatica. The four primary bioactives are:

Asiaticoside — a glycoside ester of asiatic acid, and the principal marker compound used to standardise commercial extracts. Asiaticoside is water-soluble and demonstrates particularly strong activity in collagen synthesis pathways and wound healing. It also appears to promote neurotrophin production in cell culture studies.

Madecassoside — a glycoside of madecassic acid with pronounced anti-inflammatory activity. In wound bed tissue, madecassoside suppresses pro-inflammatory cytokines and reduces fibrotic scarring, promoting orderly tissue remodelling rather than excessive scar formation.

Asiatic acid — the aglycone form of asiaticoside; more lipophilic and therefore better able to cross the blood-brain barrier than its glycosylated parent compound. Asiatic acid has been identified as the primary contributor to gotu kola's neuroprotective and neurotrophic effects in preclinical research.

Madecassic acid — the aglycone of madecassoside, contributing to anti-inflammatory and antioxidant activity. It shows synergistic activity with asiatic acid in neuroprotection studies.

The standardised extract used most extensively in clinical research is TECA (Titrated Extract of Centella Asiatica), a fraction typically standardised to approximately 40% asiaticoside, 29–30% asiatic acid, and 29–30% madecassic acid. The TECA formulation was developed in France in the 1970s and remains the reference preparation in the venous insufficiency and wound healing literature.

Beyond the four key triterpenes, gotu kola contains flavonoids including quercetin and rutin (which reinforce vascular integrity and provide antioxidant activity), a range of polyacetylenes with antimicrobial properties, and volatile oils. Evidence consistently suggests that the whole triterpenoid fraction outperforms any single isolated compound — the four triterpenes appear to act synergistically, and this is reflected in research designs that deliberately compare TECA against isolated asiaticoside or asiatic acid alone.

Mechanisms of Cognitive Action

The neurological effects of gotu kola are now understood to operate through at least four distinct mechanisms, each supported by varying degrees of evidence.

Neurotrophic factor stimulation. Asiatic acid has demonstrated the ability to stimulate the production of nerve growth factor (NGF) and brain-derived neurotrophic factor (BDNF) in neuronal cell culture models. Both NGF and BDNF are essential for the maintenance of existing synaptic connections and for the growth of new neuronal projections — a process relevant to learning, memory consolidation, and cognitive reserve as the brain ages. Gotu kola extracts have also been shown in animal studies to increase dendritic arborisation — the branching complexity of neuronal dendrites — in hippocampal neurons, which correlates functionally with improved spatial learning.

Acetylcholinesterase inhibition. Several in vitro studies have identified mild inhibitory activity against acetylcholinesterase (AChE), the enzyme that breaks down the neurotransmitter acetylcholine in the synaptic cleft. This is the same mechanistic target as pharmaceutical cholinesterase inhibitors used in Alzheimer's disease management, though gotu kola's activity is considerably less potent and is better understood as a gentle modulatory effect rather than a pharmacological blockade. Preserved acetylcholine availability is associated with improved attention, working memory, and executive function.

Anxiolytic effects via GABA modulation. Gotu kola's calming properties have been among its most consistently replicated pharmacological findings. The mechanism appears to involve modulation of GABA-A receptors — the primary inhibitory receptor system in the central nervous system — though notably not via the benzodiazepine binding site. This distinction is clinically relevant: benzodiazepine-site agonists (including pharmaceutical anxiolytics and many sedative herbs such as valerian) carry risks of tolerance, dependence, and daytime sedation. The available evidence suggests gotu kola can reduce anxiety measures without inducing sedation or impairing motor performance, which makes it functionally distinct from sedative anxiolytics.

Neuroprotection. Cell culture studies have demonstrated that asiatic acid protects neurons against oxidative stress induced by hydrogen peroxide and against amyloid-beta peptide toxicity — two injury models relevant to Alzheimer's pathology. The neuroprotective effects appear to involve both direct antioxidant scavenging and upregulation of endogenous antioxidant enzyme systems including superoxide dismutase and catalase. While these are preclinical findings, they provide a plausible mechanistic basis for the cognitive improvements observed in human trials.

Human Clinical Evidence: Cognition and Anxiety

The human clinical literature on gotu kola's cognitive effects is modest in volume but notably consistent in direction.

Wattanathorn et al. (2008) conducted a randomised, double-blind, placebo-controlled trial in 28 healthy elderly participants, administering 250mg, 500mg, or 750mg of standardised Centella asiatica extract daily over two months. The 500mg and 750mg groups showed significant improvements in working memory, speed of processing, and attention compared to baseline and placebo, along with self-reported improvements in mood. This was one of the first RCTs to demonstrate dose-dependent cognitive effects in a healthy older population.

Bradwejn et al. (2000) investigated gotu kola's anxiolytic properties using the acoustic startle response paradigm — a validated neurophysiological marker of anxiety state — in 40 healthy adults. A single oral dose of TECA extract produced a statistically significant reduction in the amplitude of the startle response compared to placebo, without altering reaction time or measures of sedation. This study is notable for using an objective physiological outcome measure rather than relying solely on self-report anxiety scales.

Pase et al. (2016) conducted a systematic review of six randomised controlled trials examining Centella asiatica preparations for cognitive or mood outcomes. The review found consistent, though modest, improvements in cognitive performance — particularly working memory and attention — across trials, with the strongest effects observed in older adult populations. Anxiolytic effects were supported across multiple trials. The authors noted limitations including small sample sizes ranging from 28 to 80 participants, short intervention durations of 4 to 12 weeks, and heterogeneity in extract standardisation across studies, calling for larger and longer trials.

The overall picture from human evidence is one of meaningful signal in a still-developing literature. The consistency of effects across independent research groups is encouraging, as is the alignment between clinical findings and the mechanistic picture from preclinical work. Standardisation remains an important variable — trials using TECA or clearly characterised extracts tend to produce more replicable results than those using poorly defined preparations. Research on gotu kola's mechanisms continues to expand, and practitioners tracking the field can access an updated botanical adaptogen research database for emerging compound-level findings.

Wound Healing and Collagen Synthesis

If gotu kola's cognitive applications represent an emerging evidence base, its wound-healing applications represent its most established and well-replicated clinical territory. TECA has been an approved pharmaceutical agent for wound healing in several European countries since the 1970s, and the evidence base here is considerably deeper than the cognitive literature.

Mechanism. Asiaticoside promotes the synthesis of collagen type I — the primary structural protein of skin, tendons, and connective tissue — by stimulating fibroblast proliferation and upregulating the transcription of collagen-encoding genes. Madecassoside simultaneously reduces pro-inflammatory signalling in the wound bed, suppressing cytokines that would otherwise impede organised tissue repair. The combined effect is accelerated granulation tissue formation, improved collagen deposition, and faster epithelialisation (resurfacing of the wound) with reduced scar thickness.

Topical clinical evidence is robust. Multiple placebo-controlled trials and comparative studies have demonstrated accelerated healing in post-surgical incision sites, reduced severity of stretch marks (striae gravidarum) in pregnant women when applied from the second trimester, and improved outcomes in superficial burns compared to standard wound care alone. The mechanism in stretch mark prevention is particularly relevant to skin ageing: gotu kola appears to maintain dermal collagen architecture under mechanical stress conditions that would otherwise induce stretch-related matrix degradation.

Oral collagen synthesis is less comprehensively studied in humans than the topical route. Animal wound models show increases in hydroxyproline content — a biochemical marker of collagen deposition — following oral TECA administration. Human studies using oral TECA for venous insufficiency have documented improvements in tissue integrity consistent with collagen synthesis effects in vascular walls and subcutaneous tissue. The relevance to skin ageing via the oral route is biologically plausible but requires more direct clinical investigation.

Matrix metalloproteinase (MMP) inhibition. Gotu kola extracts have shown activity as inhibitors of MMPs — enzymes that degrade extracellular matrix proteins including collagen. MMP overactivity is a key driver of both wound deterioration and age-related skin thinning. By moderating MMP activity alongside stimulating collagen synthesis, gotu kola addresses both sides of the collagen balance equation — production and preservation.

Venous Insufficiency: The Strongest Clinical Signal

Chronic venous insufficiency (CVI) — characterised by impaired venous return from the lower limbs, resulting in oedema, leg heaviness, aching, and skin changes — represents gotu kola's most extensively studied clinical application in Western medicine.

TECA reduces capillary permeability by strengthening the glycocalyx (the protective protein-sugar coating of vascular endothelial cells) and reinforcing the integrity of vessel walls through collagen synthesis support. This mechanistic profile directly addresses the pathophysiology of CVI, in which capillary hyperpermeability allows fluid to leak into surrounding tissue, causing characteristic oedema.

Multiple European randomised controlled trials, conducted primarily in the 1980s and 1990s when TECA was an approved pharmaceutical in France and Italy, demonstrated significant reductions in leg oedema volume, subjective heaviness, pain, and cramps in patients with CVI, compared to placebo. Effect sizes were clinically meaningful across trials.

A Cochrane systematic review of herbal medicines for CVI found that the evidence base for TECA was the most substantial among the botanicals reviewed, and supported its use for symptom relief in CVI, while noting that larger, more methodologically rigorous trials remained desirable to clarify optimal dosing parameters.

Safety Profile and Drug Interactions

Gotu kola has a well-established safety record across both traditional use and modern clinical research, with some important caveats.

Hepatotoxicity represents the most significant safety concern, primarily documented through a series of case reports rather than systematic safety studies. The mechanism is not clearly established — immune-mediated idiosyncratic toxicity is hypothesised. Cases have typically resolved upon discontinuation of gotu kola. The overall incidence appears low, but the severity of the individual cases reported warrants caution in individuals with pre-existing liver disease or those taking other hepatotoxic agents.

Drug interactions to be aware of include additive sedative effects when combined with benzodiazepines, anticonvulsants, or other CNS depressants — though this is theoretical based on gotu kola's GABAergic activity rather than documented in formal clinical interaction studies. Concurrent use with hepatotoxic medications warrants additional caution.

Pregnancy. High-dose animal studies have identified uterine-stimulating activity for gotu kola constituents. While topical use at normal concentrations is generally considered acceptable, oral supplementation is not recommended during pregnancy. This is a precautionary position based on animal data rather than documented human adverse events.

General tolerability in non-pregnant adults without liver disease is good. Clinical trials have not identified significant adverse event rates above placebo levels, and the herb has been consumed as a food in Southeast Asian cultures for generations without population-level safety signals emerging.

Dosing Considerations

Effective dosing varies by application:

For cognitive support and anxiety, the evidence base supports 500–750mg of standardised Centella asiatica extract (ideally TECA-type or with specified triterpenoid content) daily. Alternatively, 1–2g of dried herb daily has traditional support, though extract standardisation produces more predictable results. A minimum of 6–8 weeks of consistent use is appropriate before assessing response — as with adaptogenic herbs for hormonal balance, gotu kola's effects build progressively rather than appearing acutely.

For wound healing support and collagen synthesis, the reference dose from the clinical literature is 60–120mg of TECA extract containing approximately 60% total triterpenes, divided across two to three daily doses. This is a lower total plant mass dose than the cognitive application because the TECA fraction is highly concentrated.

For venous insufficiency symptom management, the doses used in European clinical trials were typically 60–120mg TECA twice daily, with trials running from 4 to 8 weeks. Significant improvements were observed within 4 weeks in most studies.

Positioning Among Cognitive Adaptogens

Within the adaptogen category, gotu kola occupies a distinct niche. Unlike Korean red ginseng and cognitive adaptogen effects, which include robust stimulant-adjacent energising properties and strong HPA axis modulation, gotu kola's cognitive profile is quieter and more specifically neurotrophic — focused on neuronal structure, memory consolidation, and anxiety reduction rather than acute mental energy.

It also differs from Siberian ginseng research findings, where the primary evidence cluster is around physical endurance, immune function, and stress resistance under load. Gotu kola's closest functional relative in the adaptogen category is arguably lion's mane mushroom (Hericium erinaceus), which shares the NGF-stimulating mechanism — though through entirely different compounds (hericenones and erinacines rather than triterpenoids).

This mechanistic specificity makes gotu kola well-suited to stack with broader-spectrum adaptogens for older adults pursuing cognitive maintenance, or as a standalone intervention for individuals whose primary concerns are anxiety and skin or connective tissue health. Its dual activity on both brain and collagen architecture is genuinely unusual in the botanical pharmacopoeia and may make it particularly relevant for women navigating post-menopausal declines in both cognitive speed and skin collagen density.

Conclusion

Gotu kola's reputation as a brain tonic and wound healer in traditional medicine is now supported by a mechanistically coherent and clinically meaningful body of evidence. Its triterpenoid compounds — asiaticoside, madecassoside, asiatic acid, and madecassic acid — act synergistically across multiple pathways: promoting neurotrophin production, mildly preserving acetylcholine availability, modulating GABA-A receptors to reduce anxiety, stimulating collagen synthesis, and inhibiting inflammatory and matrix-degrading enzyme activity.

The clinical evidence is strongest for venous insufficiency and wound healing — applications where TECA has pharmaceutical-grade trial support. The cognitive evidence is promising and consistent but remains limited by sample sizes and trial duration. Both lines of evidence are mechanistically coherent, which strengthens confidence in the biological plausibility of effects observed across study populations.

For adults over 45 seeking evidence-informed botanical support for cognitive maintenance, anxiety resilience, and connective tissue health, gotu kola represents one of the better-researched options in the adaptogen category — particularly when sourced as a standardised TECA-type extract with specified triterpenoid content.